US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Northwest Biotherapeutics, Inc.

0.2433

+0.01034.41%

Volume:1.42M

Turnover:342.55K

Market Cap:388.47M

PE:-3.73

High:0.2467

Open:0.2301

Low:0.2300

Close:0.2330

52wk High:0.4788

52wk Low:0.1685

Shares:1.60B

Float Shares:1.56B

Volume Ratio:0.80

T/O Rate:0.09%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.0652

EPS(LYR):-0.0575

ROE:276.45%

ROA:-135.39%

PB:-3.58

PE(LYR):-4.23

Loading ...

Overview Company News Filings

Northwest Biotherapeutics Cancels 17% of 2020 Management Options

Northwest Biotherapeutics Inc. held annual shareholder meeting

Northwest Biotherapeutics Secures $5 Million Convertible Loan from Yorkville Advisors

Northwest Biotherapeutics Announces That Construction Activities Are Under Way for the First Grade C Manufacturing Suite in the Sawston, UK Facility

THOMSON REUTERS

Northwest Biotherapeutics Begins Construction of Grade C Manufacturing Suite in UK Facility

Northwest Biotherapeutics Inc. Announces Date for Upcoming Annual Stockholders Meeting

Top News Today: Stocks Mixed as AI Selloff Slows

Northwest Biotherapeutics Announces That Its Acquisition of Advent Bioservices Ltd. Has Closed

THOMSON REUTERS

Northwest Biotherapeutics Secures $5.5 Million Loan from Streeterville Capital

Northwest Biotherapeutics Closes Acquisition of Advent BioServices

Northwest Biotherapeutics Closes Acquisition of Advent BioServices

Northwest Biotherapeutics Announces That Its Acquisition of Advent Bioservices Ltd. Has Closed

THOMSON REUTERS

Northwest Biotherapeutics Inc Files for Mixed Shelf of up to $250 Mln - SEC Filing

THOMSON REUTERS

Northwest Biotherapeutics Settles Option Award Litigation; Insurers to Pay $2.25 Million

Northwest Biotherapeutics to Acquire Advent BioServices, Streamlining Operations and Enhancing Scale-Up Potential

Northwest Biotherapeutics Announces Agreement to Acquire Advent Bioservices Ltd.

THOMSON REUTERS

Northwest Biotherapeutics Announces Management Changes Following Passing of Senior VP and General Counsel Les Goldman

Northwest Biotherapeutics Announces the Passing of Its Senior Vice President and General Counsel, Mr. Les Goldman

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/NWBO/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"NWBO","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NWBO\",,,,,undefined,":{"symbol":"NWBO","market":"US","secType":"STK","nameCN":"Northwest Biotherapeutics, Inc.","latestPrice":0.243265,"timestamp":1771448400000,"preClose":0.233,"halted":0,"volume":1424533,"delay":15,"changeRate":0.04405579399141629,"floatShares":1559899871,"shares":1596881409,"eps":-0.065174,"marketStatus":"Post-Mkt","change":0.010265,"latestTime":"02-18 16:00:00 EST Delay","open":0.2301,"high":0.2467,"low":0.23,"amount":342553.66125222,"amplitude":0.071674,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":-0.065174,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1771462800000},"marketStatusCode":4,"adr":0,"adrRate":0,"exchange":"OTCQB","adjPreClose":0.233,"volumeRatio":0.80207},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NWBO\",,,,,undefined,":{"symbol":"NWBO","floatShares":1559899871,"roa":"-135.39%","roe":"276.45%","lyrEps":-0.057517,"volumeRatio":0.80207,"shares":1596881409,"dividePrice":0,"high":0.2467,"amplitude":0.071674,"preClose":0.233,"low":0.23,"week52Low":0.16845,"pbRate":"-3.58","psRate":"414.58","week52High":0.4788,"institutionHeld":0.001,"latestPrice":0.243265,"eps":-0.065174,"divideRate":0,"volume":1424533,"delay":15,"ttmEps":-0.065174,"open":0.2301,"prevYearClose":0.22875,"prevWeekClose":0.24,"prevMonthClose":0.2909,"prevQuarterClose":0.2288,"fiveDayClose":0.2505,"twentyDayClose":0.2909,"sixtyDayClose":0.2378},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NWBO\",params:#limit:5,,,undefined,":[{"market":"US","date":"2024-11-12","symbol":"NWBO","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1731387600000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2024-08-09","symbol":"NWBO","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1723176000000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2024-05-10","symbol":"NWBO","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1715313600000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2024-03-05","symbol":"NWBO","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1709614800000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2023-11-09","symbol":"NWBO","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1699506000000,"reportTimeType":"post","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NWBO\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NWBO\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NWBO\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2603936701","title":"Northwest Biotherapeutics Cancels 17% of 2020 Management Options","url":"https://stock-news.laohu8.com/highlight/detail?id=2603936701","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603936701?lang=en_us&edition=fundamental","pubTime":"2026-01-16 06:06","pubTimestamp":1768514809,"startTime":"0","endTime":"0","summary":"Northwest Biotherapeutics Inc. has announced the cancellation of 17% of the challenged 2020 option awards to company management and directors as part of a settlement agreement related to litigation in the Delaware Court of Chancery. Under the terms of the settlement, the company’s insurance carriers will pay $2.25 million to the company, and all claims between the parties will be fully resolved.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Northwest Biotherapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 15, 2026, and is solely responsible for the information contai","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260115:nNDL8GNvtN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NWBO"],"gpt_icon":0},{"id":"2600109531","title":"Northwest Biotherapeutics Inc. held annual shareholder meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2600109531","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2600109531?lang=en_us&edition=fundamental","pubTime":"2026-01-03 06:15","pubTimestamp":1767392144,"startTime":"0","endTime":"0","summary":"Northwest Biotherapeutics Inc. held its annual meeting of stockholders on December 29, 2025. At the meeting, shareholders approved the election of Pat Sarma to the Board of Directors. The appointment of Cherry Bekaert LLP as independent registered public accounting firm for the fiscal year ending December 31, 2025 was also ratified. In addition, shareholders approved an amendment to increase the number of authorized shares of common stock from 1.7 billion to 2.6 billion.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Northwest Biotherapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commissio","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260102:nNDL6psf1F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NWBO"],"gpt_icon":0},{"id":"2585215019","title":"Northwest Biotherapeutics Secures $5 Million Convertible Loan from Yorkville Advisors","url":"https://stock-news.laohu8.com/highlight/detail?id=2585215019","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585215019?lang=en_us&edition=fundamental","pubTime":"2025-11-21 05:26","pubTimestamp":1763673997,"startTime":"0","endTime":"0","summary":"Northwest Biotherapeutics Inc. has entered into a $5 million convertible promissory note financing agreement with YA II PN, Ltd., an investment fund managed by Yorkville Advisors Global, LP. The proceeds from this financing will be used to help cover construction and equipment costs for the company's first Grade C manufacturing suite at its Sawston, UK facility, as well as for ongoing operations. The note has a 12-month term, with no payments due until maturity, carries a five percent original issue discount but no interest, and may be converted at the option of the holder at a small discount to the prevailing market price, subject to monthly conversion limits unless the conversion price exceeds $0.29.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251120:nNDLbMYlpQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NWBO"],"gpt_icon":0},{"id":"2585152693","title":"Northwest Biotherapeutics Announces That Construction Activities Are Under Way for the First Grade C Manufacturing Suite in the Sawston, UK Facility","url":"https://stock-news.laohu8.com/highlight/detail?id=2585152693","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585152693?lang=en_us&edition=fundamental","pubTime":"2025-11-21 03:58","pubTimestamp":1763668719,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251120:nTUA1S6Q3P:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NWBO","BK4139"],"gpt_icon":0},{"id":"2585523541","title":"Northwest Biotherapeutics Begins Construction of Grade C Manufacturing Suite in UK Facility","url":"https://stock-news.laohu8.com/highlight/detail?id=2585523541","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585523541?lang=en_us&edition=fundamental","pubTime":"2025-11-21 03:41","pubTimestamp":1763667666,"startTime":"0","endTime":"0","summary":"Northwest Biotherapeutics Inc. has begun construction on its first Grade C manufacturing suite at its Sawston, UK facility, signaling a significant expansion of its production capabilities. The new suite, expected to more than double the current aggregate capacity of existing Grade B suites, represents a major step toward large-scale manufacturing of the company's DCVax personalized immune therapies for solid tumor cancers. Construction is projected to take approximately six months, with manufacturing in the new suite anticipated to begin in the second quarter of next year. The upgrade leverages the Flaskworks closed system, enabling the transition from Grade B to Grade C suites and supporting the company's plans for large-scale operations.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be in","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251120:nNDLc97BKy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NWBO"],"gpt_icon":0},{"id":"2584997545","title":"Northwest Biotherapeutics Inc. Announces Date for Upcoming Annual Stockholders Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2584997545","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584997545?lang=en_us&edition=fundamental","pubTime":"2025-11-20 05:17","pubTimestamp":1763587035,"startTime":"0","endTime":"0","summary":"Northwest Biotherapeutics, Inc. will hold its 2025 Annual Meeting of Stockholders on December 29, 2025. The meeting will take place at the offices of Gibson, Dunn & Crutcher LLP in Washington, DC.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Northwest Biotherapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 19, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nNDL3BP2kS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NWBO"],"gpt_icon":0},{"id":"2583682607","title":"Top News Today: Stocks Mixed as AI Selloff Slows","url":"https://stock-news.laohu8.com/highlight/detail?id=2583682607","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583682607?lang=en_us&edition=fundamental","pubTime":"2025-11-15 05:45","pubTimestamp":1763156700,"startTime":"0","endTime":"0","summary":"TREASURYS: Treasury yields rose amid doubts about the Federal Reserve's next move.COMMODITIES: Oil futures rose after Ukraine drone attacks on a Russian Black Sea port.Walmart picked one of its longtime executives, John Furner, to become its next chief executive, preserving its tradition of promoting an insider to steer the nation's biggest retailer. The 51-year-old Furner was seen inside the company as the likely heir apparent and ready for his next step after six years leading Walmart's U.S. business. Outside the company, the Walmart veteran-and son of a Walmart executive-was seen as a potential CEO candidate for other firms too.The reopened federal government will on Thursday release the first backlogged monthly jobs report, for the month of September. And a flood of other data is due to start flowing soon.They promised investments in the U.S. that would reduce Switzerland's trade imbalance with the U.S., according to people familiar wit","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SRG","IE00B2B36J28.USD","STI","ALBT","GPUS","KALA","RHEP","LU0061474960.USD","XP","LFMD","LU0203347892.USD","JJSF","BK4007","LU2750360641.GBP","UAVS","HP","SPRB","PRPO","LU1430594728.SGD","LU1066053197.SGD","LU2468319806.SGD","BK4211","IIIV","IPAR","PNBK","NWBO","LU2430703178.SGD","BYFC","MRK","LU2430703251.USD","OTLC","BK4152","LU2023250843.SGD","LU1974910355.USD","TVGN","ARMK","LITS","ALTS","LWLG","LU2361044865.SGD","BK4561","BRC","LU0861579265.USD","LU2592432038.USD","ASPI","WMT","AAME","TORM","ELDN"],"gpt_icon":0},{"id":"2580479335","title":"Northwest Biotherapeutics Announces That Its Acquisition of Advent Bioservices Ltd. Has Closed","url":"https://stock-news.laohu8.com/highlight/detail?id=2580479335","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580479335?lang=en_us&edition=fundamental","pubTime":"2025-11-02 03:16","pubTimestamp":1762024561,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251101:nTUA65R4RJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","NWBO"],"gpt_icon":0},{"id":"2580491292","title":"Northwest Biotherapeutics Secures $5.5 Million Loan from Streeterville Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2580491292","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580491292?lang=en_us&edition=fundamental","pubTime":"2025-11-01 00:29","pubTimestamp":1761928184,"startTime":"0","endTime":"0","summary":"Northwest Biotherapeutics Inc. has entered into a new commercial loan agreement with Streeterville Capital, LLC for $5,505,000. The loan, signed on October 27, 2025, has a maturity of 22 months and features no repayments for the first eight months, with repayments beginning June 26, 2026. After this period, the loan will be repaid in 14 equal monthly installments of principal at 110% of the pro rata amount, plus accrued interest at an annual rate of 8%. The agreement includes a 10% original issue discount and allows for pre-payment at the company's discretion, subject to a 10% pre-payment charge. The funds will be used to support ongoing business operations.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Northwest Biotherapeutics Inc. ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251031:nNDL8MjPMj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NWBO","BK4139"],"gpt_icon":0},{"id":"2579170685","title":"Northwest Biotherapeutics Closes Acquisition of Advent BioServices","url":"https://stock-news.laohu8.com/highlight/detail?id=2579170685","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579170685?lang=en_us&edition=fundamental","pubTime":"2025-10-31 04:40","pubTimestamp":1761856852,"startTime":"0","endTime":"0","summary":"Northwest Biotherapeutics, Inc. has completed its acquisition of Advent BioServices Ltd., making Advent a wholly owned subsidiary. As part of the deal, Northwest Biotherapeutics receives all of Advent's fixed assets, including cryostorage and equipment, as well as intellectual property and other intangibles previously held by Advent. No new shares or securities are being issued; instead, 19 million previously issued securities to Advent, consisting of 13.5 million shares and 5.5 million options, are reverting back to Northwest Biotherapeutics. Payment for the acquisition will be made in installments over two years, with the potential for acceleration following regulatory approval of the DCVax-L product. The consideration includes 1.4 million and payment of the net accounts payable due for past services, with installment payments scheduled to begin 90 days after the October closing.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251030:nNDL7Rpl9y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NWBO"],"gpt_icon":0},{"id":"2578545686","title":"Northwest Biotherapeutics Closes Acquisition of Advent BioServices","url":"https://stock-news.laohu8.com/highlight/detail?id=2578545686","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578545686?lang=en_us&edition=fundamental","pubTime":"2025-10-25 00:03","pubTimestamp":1761321838,"startTime":"0","endTime":"0","summary":"Northwest Biotherapeutics has completed the acquisition of Advent BioServices Ltd., making Advent a wholly owned subsidiary. The company expects the integration to enable efficiencies and scale-up of operations, including streamlining supply chain and facilities management, reallocating resources from the London GMP facility to the Sawston, UK facility and U.S. capacity, and facilitating manufacturing scale-up. As part of the transaction, 19 million previously issued NWBio securities are reverting back to the company, and NWBio is acquiring all of Advent's fixed assets, intellectual property, and other intangibles. The payment for the acquisition will be made in installments over two years, with potential acceleration after regulatory approval of DCVax-L, and includes 1.4 million and net accounts payable due for prior contract services.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and tim","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251024:nNDL7mYqMs:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NWBO","BK4139"],"gpt_icon":0},{"id":"2578545575","title":"Northwest Biotherapeutics Announces That Its Acquisition of Advent Bioservices Ltd. Has Closed","url":"https://stock-news.laohu8.com/highlight/detail?id=2578545575","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578545575?lang=en_us&edition=fundamental","pubTime":"2025-10-25 00:03","pubTimestamp":1761321817,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251024:nTUA10XZMH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NWBO","BK4139"],"gpt_icon":0},{"id":"2577980594","title":"Northwest Biotherapeutics Inc Files for Mixed Shelf of up to $250 Mln - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2577980594","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577980594?lang=en_us&edition=fundamental","pubTime":"2025-10-24 18:03","pubTimestamp":1761300196,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251024:nFWN3W52S3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NWBO","BK4139"],"gpt_icon":0},{"id":"2575486246","title":"Northwest Biotherapeutics Settles Option Award Litigation; Insurers to Pay $2.25 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2575486246","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575486246?lang=en_us&edition=fundamental","pubTime":"2025-10-15 02:23","pubTimestamp":1760466194,"startTime":"0","endTime":"0","summary":"Northwest Biotherapeutics Inc. has reached a settlement agreement to resolve litigation in the Delaware Court of Chancery regarding option awards made to its management and directors in 2020. According to the terms, 17% of the disputed 2020 options will be cancelled, and the company will receive a $2.25 million payment from its insurance carriers. The settlement, which also addresses claims in an amended complaint filed in October 2025, is subject to court approval. The plaintiff is expected to seek attorneys' fees and expenses, which will be paid separately by the company's insurers and not from the settlement funds. Both parties are working to finalize the settlement documentation within thirty days.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251014:nNDL6Lzv80:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NWBO"],"gpt_icon":0},{"id":"2562265197","title":"Northwest Biotherapeutics to Acquire Advent BioServices, Streamlining Operations and Enhancing Scale-Up Potential","url":"https://stock-news.laohu8.com/highlight/detail?id=2562265197","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562265197?lang=en_us&edition=fundamental","pubTime":"2025-08-28 00:39","pubTimestamp":1756312766,"startTime":"0","endTime":"0","summary":"Northwest Biotherapeutics, Inc. has announced an agreement to acquire Advent BioServices Ltd. from Toucan Holdings LLC. Upon completion of the transaction, Advent will become a wholly owned subsidiary, allowing Northwest Biotherapeutics to integrate its manufacturing and product development operations internally. This acquisition is expected to enhance operational scalability and yield cost efficiencies. The agreement includes the transfer of Advent's fixed assets and intellectual property to Northwest Biotherapeutics, along with 19 million NWBio securities previously issued to Advent. Payment for the acquisition will be made in installments over two years, starting 90 days post-agreement, with potential acceleration contingent on regulatory approval of the DCVax-L product.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250827:nNDL3VnKkz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NWBO"],"gpt_icon":0},{"id":"2562388726","title":"Northwest Biotherapeutics Announces Agreement to Acquire Advent Bioservices Ltd.","url":"https://stock-news.laohu8.com/highlight/detail?id=2562388726","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562388726?lang=en_us&edition=fundamental","pubTime":"2025-08-28 00:39","pubTimestamp":1756312752,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250827:nTUA7SGPLQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NWBO","BK4139"],"gpt_icon":0},{"id":"2560184927","title":"Northwest Biotherapeutics Announces Management Changes Following Passing of Senior VP and General Counsel Les Goldman","url":"https://stock-news.laohu8.com/highlight/detail?id=2560184927","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2560184927?lang=en_us&edition=fundamental","pubTime":"2025-08-19 00:37","pubTimestamp":1755535077,"startTime":"0","endTime":"0","summary":"Northwest Biotherapeutics Inc. has announced changes in its management team following the passing of its Senior Vice President and General Counsel, Mr. Les Goldman. His responsibilities are being taken over by other members of the company's management team.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Northwest Biotherapeutics Inc. published the original content used to generate this news brief via PR Newswire  on August 18, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250818:nNDL4Cf6wr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NWBO","BK4139"],"gpt_icon":0},{"id":"2560849741","title":"Northwest Biotherapeutics Announces the Passing of Its Senior Vice President and General Counsel, Mr. Les Goldman","url":"https://stock-news.laohu8.com/highlight/detail?id=2560849741","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2560849741?lang=en_us&edition=fundamental","pubTime":"2025-08-19 00:37","pubTimestamp":1755535065,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250818:nTUAC3HLM3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NWBO","BK4139"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":18,"code":"91000000","status":"200"}]}}